Brightmeds Review

Brightmeds LLC operates the consumer platform and coordinates intake, records, payment, clinician access, and prescription fulfillment. The terms say Brightmeds itself is not the healthcare provider. A patient relationship forms with an affiliated medical group or clinician, and an independent pharmacy dispenses an approved prescription.

The current relationship section names M & D Integrations and TelegraMD as possible medical groups. A later telehealth-consent section names Vital, OpenLoop Healthcare Partners, and several affiliated Reliant medical entities. Those lists can both describe the network, but they do not tell a new patient which professional entity or clinician will handle a particular request.

Beaker Pharmacy and Red Rock Pharmacy are named as portal fulfillment options, and the terms reserve room for other pharmacy partnerships. This is useful disclosure, but it is not a patient-specific assignment. The prescription notice and pharmacy label should identify the actual prescriber, medical group, pharmacy, active ingredient, concentration, additives, quantity, storage conditions, and beyond-use date.

The public flow begins with a product and state selection followed by a health intake and payment information. For GLP-1 subscriptions, Brightmeds describes an authorization hold rather than an immediate charge while an affiliated clinician reviews the request, typically within 24 hours. If review is still pending after five days, the policy permits a charge before a final decision.

Six active ingredients support the compact treatment section: semaglutide, tirzepatide, testosterone cypionate, NAD+, sermorelin, and glutathione. Microdosing is a protocol, not a medication. Workout & Recovery and Energy & Recovery are marketing labels, not active ingredients. Testosterone cream and oral capsules remain route variants because exact product-level details are missing.

The current Summer Special lists compounded semaglutide at $129 for one month or $297 prepaid for three months, equivalent to $99 per month. Compounded tirzepatide is $149 for one month or $357 prepaid for three months, equivalent to $119 per month. The offer says medication at any prescribed dose, evaluation, follow-up, dose adjustments, support, and standard shipping are included.

Those GLP-1 figures are compact on the cards but not used as standard averages. The page is explicitly seasonal, and its terms do not publish a final enrollment date. A separate policy says the promotional recurring price remains locked while enrollment stays continuously active, but the patient should still retain the order confirmation and renewal notice.

The Summer Special is narrower than the general service claim. It lists 38 jurisdictions, including Washington, D.C., while the general terms say Brightmeds operates in 47 states except Alabama, Arkansas, and Mississippi. Product, route, dose, clinician, and pharmacy availability can be narrower, so the selected treatment and delivery address control.

Brightmeds also offers access to Zepbound pens and vials through a different billing model. The products page lists a $100 Brightmeds consultation fee, then directs the prescription to LillyDirect or a local pharmacy where the medication cost is separate. This is not comparable with the bundled compounded GLP-1 price and therefore does not receive another card.

The main TRT program advertises a flat $75 per week with no membership fee. It says three laboratory panels for the first year, consultation, one month of medication and supplies, shipping, support, and quarterly follow-up are included. Treatment is limited to men whose clinician evaluation and laboratory work support medically appropriate testosterone therapy.

A separate product page creates a material pricing conflict. It identifies testosterone cypionate at 200 mg/mL in a 5 mL vial for $299 as a one-time purchase, lists $299 monthly, and presents a three-month plan with $166 for the first month and $266 afterward. The page does not reconcile those figures with the $75-per-week all-inclusive program.

The cypionate injection is the only exact testosterone product mapped to the catalog. Brightmeds also describes cream and oral capsule routes, but it does not publish their exact ingredient form, strength, quantity, or route-specific price. The cypionate card therefore withholds a monthly comparison figure instead of blending dissimilar programs.

NAD+ has four comparable continuation rates: $155 per month on a twelve-month term, $175 on six months, $199 on two months, and $246 month-to-month. Their unweighted arithmetic mean is $193.75, rounded to Avg. $194/mo. The concentration and vial quantity are not public, so the card stays outside dose-level comparison.

The longer NAD+ options are not ordinary monthly billing. The page says twelve-, six-, and two-month terms are billed at the start of the term and shipped every two months. The displayed $50 first-order discount produces first-month headlines of $105, $124, $148, or $196. Based on the displayed components, first-term totals reconstruct to $1,810, $999, $347, and $196, but checkout should confirm the actual amount charged.

The sermorelin page lists a 6 mL vial at 2.5 mg/mL for $196 as a one-month supply with supplies and free shipping. The same page says $50 is saved on the first order without stating whether the displayed total already includes that discount. The card uses the fully visible $196 amount and remains outside comparison.

The glutathione page lists a 10 mL vial at 200 mg/mL for $119 as a one-month supply with consultation, shipping, and support. An earlier section says starting at $99 without tying that amount to a term, quantity, or eligibility rule. The card uses $119 and flags the unresolved headline.

The current NAD+, sermorelin, glutathione, and testosterone pages say HSA/FSA eligible. That is a provider statement, not a guarantee that a card administrator will approve a particular expense. Brightmeds is primarily a cash-pay service, and the current GLP-1 offer says insurance is not required.

General terms describe a $100 initial laboratory cost for some programs. It is included when the customer proceeds, but it is deducted and non-refundable when the customer stops after the test. The current TRT offer separately says three first-year panels are free, so a customer should retain the treatment-specific checkout record rather than apply the general rule to every program.

GLP-1 monthly subscriptions renew automatically. Cancellation must reach support by email or phone at least five business days before the next renewal, and a late request may not take effect until the following cycle. Once medication has been compounded, dispensed, or shipped, the current order cannot be stopped or returned.

If an affiliated clinician finds the patient ineligible, Brightmeds says the hold or captured charge is returned. Approved refunds of captured payments are described as taking five to ten business days. Outside a more specific policy, the general terms characterize fees as non-refundable, so the exact product policy at checkout matters.

The terms say pharmacies ship new prescriptions in three to eight business days and that most clients receive medication within one week after the prescription is generated. Several treatment pages include free shipping. Neither statement guarantees the assigned pharmacy, clinical review time, carrier service, temperature handling, or delivery date for every order.

Customer support is available by email, patient portal, and 1-888-818-7517. The current GLP-1 policy publishes Monday through Friday hours from 9 a.m. to 6 p.m. Eastern. No response-time target, weekend schedule, or emergency clinical channel is promised.

Compounded semaglutide, tirzepatide, testosterone, sermorelin, NAD+, and glutathione are not FDA approved. FDA does not review compounded prescriptions before marketing for safety, effectiveness, or quality. A pharmacy license, state regulation, or outsourcing-facility registration is not approval of the individual product.

Brightmeds publishes treatment-specific safety pages and direct instruction pages, which helps a patient locate basic warnings and administration material. Some marketing copy goes further than the service and pricing evidence supports, and one privacy-policy sentence uses Brightmeds Inc. while the operative terms use Brightmeds LLC. The final prescription notice and legal checkout record should control.

Four Katalys applications are pending for sermorelin, NAD+, TRT, and glutathione, each with a recorded $40 sale payout. No issued tracking link or affiliate-compatible customer promotion is available. The unpublished CTA therefore uses the canonical Brightmeds domain and displays no promotional line.